Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update
Published date:
04/19/2022
Excerpt:
Recommendation...a patient with node-positive breast cancer with a high risk of recurrence and a Ki67 score of ≥ 20% as determined by an FDA-approved test may be offered two years of abemaciclib plus endocrine therapy...